October 16, 2019 / 10:42 AM / a month ago

Drugmaker Alexion to buy biotech Achillion in $930 mln deal

Oct 16 (Reuters) - Alexion Pharmaceuticals Inc on Wednesday agreed to buy small biotech Achillion Pharmaceuticals Inc in a $930 million deal, to boost its pipeline of rare disease treatments.

Alexion's offer of $6.30 per share represents a premium of 72.6% to Achillion stock's close on Tuesday.

The deal is expected to close in the first half of 2020, the companies said. (Reporting by Tamara Mathias in Bengaluru; Editing by Sriraj Kalluvila)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below